AACR 2022 | How NK therapies are transforming the treatment landscape of Hodgkin lymphoma
Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the promise of novel natural killer (NK) therapies in the treatment of Hodgkin lymphoma (HL). Prof. Nieto first explains the role of brentuximab vedotin in the treatment of HL, and the need provide more options for patients who relapse or do not respond to this therapy. Prof. Nieto then explains the benefits of using NK cells, including the high activity and safety profiles demonstrated in various studies. To conclude, Prof. Nieto highlights the lower cost associated with manufacturing NK cells, as well as their ability to target various tumors. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
